0       0

AMDA's 2016 Annual Conference


208 - Drug-Induced Parkinsonism Versus Idiopathic Parkinson's Disease


Mar 18, 2016 11:00am ‐ Mar 18, 2016 12:00pm


Credits: None available.

Standard: $24.00

Description

Accreditation Statement: AMDA – The Society for Post-Acute and Long-Term Care Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement: AMDA – The Society for Post-Acute and Long-Term Care Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABPLM Designation Statement: This internet enduring material has been pre-approved by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) for a total of 1 clinical hour toward certification as a Certified Medical Director (CMD) in post-acute and long-term care medicine. The CMD program is administered by the ABPLM.  Each physician should claim only those hours of credit actually spent on the activity. 

Session Description:
This session will outline the primary symptoms of drug-induced parkinsonism as well as tardive dyskinesia, akathisia and other movement disorders. Causative agents, diagnostics and potential treatments will be discussed. We will also describe how the introduction of dopamine blocking medications might “unmask” prodromal idiopathic Parkinson disease symptoms, sometimes confounding proper diagnosis. Case presentations will provide a platform for differential diagnosis of traditional idiopathic Parkinson’s disease in contrast with drug-induced parkinsonism and the respective treatment approaches for each of these disorders.

Learning Objective(s):

  • Highlight difference between symptoms associated with idiopathic Parkinson's disease (IPD) and symptoms associated with drug-induced parkinsonism.
  • Outline treatment approaches for addressing drug-induced Parkinson's.
  • Identify differences in treatment approaches appropriate for early, mid-stage and late stage idiopathic Parkinson's disease.
Speaker(s):
Nora A. Reznickova, MD
John M. Dean, MA, CCC-SLP

Disclosure(s):
None

Reference(s):
None

Speaker(s):

Credits

  • 1.00 - Clinical
  • 1.00 - CME

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content